Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 17 studies | 32% ± 19% | |
peripheral blood | 14 studies | 21% ± 6% | |
lung | 9 studies | 24% ± 7% | |
liver | 5 studies | 25% ± 12% | |
heart | 4 studies | 23% ± 5% | |
kidney | 4 studies | 20% ± 4% | |
adipose | 4 studies | 26% ± 5% | |
bone marrow | 3 studies | 25% ± 6% | |
eye | 3 studies | 29% ± 17% | |
intestine | 3 studies | 18% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 5471.28 | 1445 / 1445 | 100% | 36.36 | 183 / 183 |
breast | 100% | 6026.21 | 459 / 459 | 100% | 32.65 | 1115 / 1118 |
brain | 100% | 3710.10 | 2633 / 2642 | 100% | 26.54 | 705 / 705 |
lung | 100% | 6917.04 | 578 / 578 | 100% | 24.51 | 1151 / 1155 |
prostate | 100% | 6249.29 | 245 / 245 | 100% | 26.51 | 500 / 502 |
thymus | 100% | 9634.26 | 653 / 653 | 100% | 37.98 | 602 / 605 |
stomach | 100% | 4084.49 | 358 / 359 | 100% | 24.54 | 285 / 286 |
uterus | 100% | 6261.39 | 170 / 170 | 99% | 21.55 | 456 / 459 |
intestine | 100% | 6426.79 | 966 / 966 | 99% | 21.98 | 523 / 527 |
bladder | 100% | 6214.86 | 21 / 21 | 98% | 19.04 | 496 / 504 |
pancreas | 99% | 2588.16 | 324 / 328 | 99% | 24.19 | 176 / 178 |
kidney | 100% | 4079.08 | 89 / 89 | 97% | 23.89 | 876 / 901 |
ovary | 100% | 5693.03 | 180 / 180 | 95% | 11.88 | 408 / 430 |
skin | 100% | 5932.95 | 1809 / 1809 | 94% | 25.64 | 445 / 472 |
adrenal gland | 100% | 4906.82 | 258 / 258 | 94% | 16.06 | 216 / 230 |
liver | 100% | 3240.63 | 226 / 226 | 92% | 11.37 | 372 / 406 |
adipose | 100% | 6324.95 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 5753.13 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 37.87 | 29 / 29 |
spleen | 100% | 10446.51 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 27.94 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 5.11 | 1 / 1 |
muscle | 100% | 3446.63 | 801 / 803 | 0% | 0 | 0 / 0 |
heart | 98% | 3575.71 | 848 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 98% | 6079.58 | 909 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 78% | 12.22 | 62 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0032508 | Biological process | DNA duplex unwinding |
GO_0006376 | Biological process | mRNA splice site recognition |
GO_0007283 | Biological process | spermatogenesis |
GO_0010976 | Biological process | positive regulation of neuron projection development |
GO_0033120 | Biological process | positive regulation of RNA splicing |
GO_0006396 | Biological process | RNA processing |
GO_0006302 | Biological process | double-strand break repair |
GO_0006974 | Biological process | DNA damage response |
GO_0007623 | Biological process | circadian rhythm |
GO_0006369 | Biological process | termination of RNA polymerase II transcription |
GO_0060566 | Biological process | positive regulation of termination of DNA-templated transcription |
GO_0034599 | Biological process | cellular response to oxidative stress |
GO_0030154 | Biological process | cell differentiation |
GO_2000144 | Biological process | positive regulation of DNA-templated transcription initiation |
GO_2000806 | Biological process | positive regulation of termination of RNA polymerase II transcription, poly(A)-coupled |
GO_0006310 | Biological process | DNA recombination |
GO_0006353 | Biological process | DNA-templated transcription termination |
GO_0007399 | Biological process | nervous system development |
GO_0070301 | Biological process | cellular response to hydrogen peroxide |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005730 | Cellular component | nucleolus |
GO_0000228 | Cellular component | nuclear chromosome |
GO_0005654 | Cellular component | nucleoplasm |
GO_0045171 | Cellular component | intercellular bridge |
GO_0016604 | Cellular component | nuclear body |
GO_0030426 | Cellular component | growth cone |
GO_0005737 | Cellular component | cytoplasm |
GO_0030424 | Cellular component | axon |
GO_0000781 | Cellular component | chromosome, telomeric region |
GO_0005634 | Cellular component | nucleus |
GO_0003677 | Molecular function | DNA binding |
GO_0016787 | Molecular function | hydrolase activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0003678 | Molecular function | DNA helicase activity |
GO_0005524 | Molecular function | ATP binding |
GO_0003723 | Molecular function | RNA binding |
GO_0005515 | Molecular function | protein binding |
GO_0001147 | Molecular function | transcription termination site sequence-specific DNA binding |
Gene name | SETX |
Protein name | Senataxin isoform 2 Senataxin Probable helicase senataxin (EC 3.6.4.-) (Amyotrophic lateral sclerosis 4 protein) (SEN1 homolog) (Senataxin) Senataxin isoform 1 |
Synonyms | ALS4 KIAA0625 SCAR1 |
Description | FUNCTION: Probable RNA/DNA helicase involved in diverse aspects of RNA metabolism and genomic integrity. Plays a role in transcription regulation by its ability to modulate RNA Polymerase II (Pol II) binding to chromatin and through its interaction with proteins involved in transcription . Contributes to the mRNA splicing efficiency and splice site selection . Required for the resolution of R-loop RNA-DNA hybrid formation at G-rich pause sites located downstream of the poly(A) site, allowing XRN2 recruitment and XRN2-mediated degradation of the downstream cleaved RNA and hence efficient RNA polymerase II (RNAp II) transcription termination . Required for the 3' transcriptional termination of PER1 and CRY2, thus playing an important role in the circadian rhythm regulation (By similarity). Involved in DNA double-strand breaks damage response generated by oxidative stress . In association with RRP45, targets the RNA exosome complex to sites of transcription-induced DNA damage . Plays a role in the development and maturation of germ cells: essential for male meiosis, acting at the interface of transcription and meiotic recombination, and in the process of gene silencing during meiotic sex chromosome inactivation (MSCI) (By similarity). May be involved in telomeric stability through the regulation of telomere repeat-containing RNA (TERRA) transcription . Plays a role in neurite outgrowth in hippocampal cells through FGF8-activated signaling pathways. Inhibits retinoic acid-induced apoptosis . . |
Accessions | ENST00000224140.6 [Q7Z333-1] ENST00000436441.5 A0A0S2Z520 Q7Z333 X6RI79 A0A0S2Z550 |